Sep 12 2025 This Week in Cardiology
This Week in Cardiology
Medscape Podcasts
4.9 • 963 Ratings
🗓️ 12 September 2025
⏱️ 31 minutes
🧾️ Download transcript
Summary
More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I New European Valvular Heart Disease Guidelines
- 2025 ESC/EACTS Guidelines for the management of valvular heart disease https://doi.org/10.1093/eurheartj/ehaf194
- Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/
- Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528
- Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336
II New Drug for Resistant HTN
- Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7
- Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109
- Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440
III HCM News at ESC
- New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv
- MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654
- SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424
- ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927
IV Vericiguat at ESC
- New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9
- VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4
- VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928
- An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4
V More on Digoxin
- RATE AF substudy https://doi.org/10.1002/ejhf.70022
- Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407
- Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology. |
| 0:05.7 | This podcast is intended for health care professionals only. |
| 0:08.8 | Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape. |
| 0:14.9 | Hi, everyone. |
| 0:16.4 | This is John Mandrola from the Heart.org Medscape Cardiology, and this is this week in cardiology for September 12, 2025. |
| 0:26.4 | This week, a correction, some more ESC studies, including valvular heart disease guidelines, a new drug class for hypertension, |
| 0:36.7 | mycison inhibition and hypertrophic cardiomyopathy, vericiguet, |
| 0:41.2 | and more dejoxin news. |
| 0:43.8 | First up is a correction. |
| 0:45.7 | The PI of the Dan Block trial, Professor Eva Prescott from the University of Copenhagen, emailed me some comments. |
| 0:52.2 | First of all, that's a nice thing to get an email from Copenhagen and from a |
| 0:56.6 | PI. Less nice is that I made an error both in my column on Medscape and on my podcast last week |
| 1:03.8 | about the reboot trial, the Spanish RCT of Postamai beta blockers. I said and wrote, 4,000 patients were randomized. That is wrong. |
| 1:13.9 | It was actually 4,000 per arm for a total of 8,000, so sorry for the mistake. |
| 1:19.9 | Professor Prescott also disagreed with my less than enthusiastic embrace of the subgroup |
| 1:24.8 | finding in patients with mild delvee dysfunction, |
| 1:29.7 | EF 40 to 49%. She felt that while the absolute risk reduction of one event per 100 patient years is not |
| 1:34.6 | dramatic, the relative risk reduction of 25% is on par with statins and aspirin, |
| 1:40.8 | quote, in that context, beta blockers may still have a role. They are inexpensive, |
| 1:45.8 | safe, and have been part of cardiovascular care for decades. Moreover, studies in heart failure |
| 1:51.1 | with LVEF, 40 to 55 percent, including a meta-analysis by Cleland at all, suggests benefit |
| 1:56.9 | and these patients groups overlap considerably. Thank you, Professor Prescott. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.